Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claude Schulman

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
BJU International|December 13, 2005
Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasiaClaude Schulman, Peter Pommerville, Klaus Höfner, et al.
European Urology|August 10, 2013
European urology: quality, impact, onlineJames W F Catto, Francesco Montorsi, Claude Schulman
The New England Journal of Medicine|December 22, 2006
Use of statins and outcome of BCG treatment for bladder cancerPaul Hoffmann, Thierry Roumeguère, Claude Schulman, et al.
Current Opinion in Urology|February 24, 2005
Laparoscopic radical prostatectomy: the learning curveRenaud Bollens, Sarbjinder Sandhu, Thierry Roumeguere, et al.
The Journal of Sexual Medicine|December 19, 2008
Health-related quality of life instruments in studies of adult men with testosterone deficiency syndrome: a critical assessmentSue Langham, Mario Maggi, Claude Schulman, et al.
The Journal of Sexual Medicine|July 14, 2007
The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impactMario Maggi, Claude Schulman, Richard Quinton, et al.
BJU International|March 24, 2009
Prostate cancer: a serious disease suitable for preventionJohn M Fitzpatrick, Claude Schulman, Alexandre R Zlotta, et al.
European Urology|August 28, 2007
Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literatureVincenzo Scattoni, Alexandre Zlotta, Rodolfo Montironi, et al.
BJU International|September 28, 2007
Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancerClaude Schulman, Antonio Alcaraz, Richard Berges, et al.
BJU International|February 26, 2009
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?Thierry Roumeguère, K Zouaoui Boudjeltia, Claude Hauzeur, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
BJU International|December 13, 2005
Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasiaClaude Schulman, Peter Pommerville, Klaus Höfner, et al.
European Urology|August 10, 2013
European urology: quality, impact, onlineJames W F Catto, Francesco Montorsi, Claude Schulman
The New England Journal of Medicine|December 22, 2006
Use of statins and outcome of BCG treatment for bladder cancerPaul Hoffmann, Thierry Roumeguère, Claude Schulman, et al.
Current Opinion in Urology|February 24, 2005
Laparoscopic radical prostatectomy: the learning curveRenaud Bollens, Sarbjinder Sandhu, Thierry Roumeguere, et al.
The Journal of Sexual Medicine|December 19, 2008
Health-related quality of life instruments in studies of adult men with testosterone deficiency syndrome: a critical assessmentSue Langham, Mario Maggi, Claude Schulman, et al.
The Journal of Sexual Medicine|July 14, 2007
The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impactMario Maggi, Claude Schulman, Richard Quinton, et al.
BJU International|March 24, 2009
Prostate cancer: a serious disease suitable for preventionJohn M Fitzpatrick, Claude Schulman, Alexandre R Zlotta, et al.
European Urology|August 28, 2007
Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literatureVincenzo Scattoni, Alexandre Zlotta, Rodolfo Montironi, et al.
BJU International|September 28, 2007
Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancerClaude Schulman, Antonio Alcaraz, Richard Berges, et al.
BJU International|February 26, 2009
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?Thierry Roumeguère, K Zouaoui Boudjeltia, Claude Hauzeur, et al.
Pageof 5